Guardant Health AMEA
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for amivantamab-vmjw to identify patients with inoperable or recurrent NSCLC harbouring EGFR exon 20 insertion mutations
August 30, 2024 TOKYO — Guardant Health Japan Corp. (HQ: Minato-ku, Tokyo/ Representative Director: Mika Takaki), a leading precision oncology company, today announced that the
Guardant Health Japan submits application for regulatory approval of Guardant360® CDx in Japan as companion diagnostic for Janssen lung cancer therapy
July 17, 2024 TOKYO – Guardant Health Japan Corp. (HQ: Minato-ku,Tokyo/ AMEA CEO Simranjit Singh, Japan Representative Director Mika Takaki) announced it
First batch of blood samples has been tested for prospective clinical trials using the Guardant360® liquid biopsy in the Adicon laboratory in China
May 16, 2024 HANGZHOU, China — Adicon Holdings Limited, a leading independent clinical laboratory company, announced today that it has completed processing
Adicon offers GuardantOMNI® liquid biopsy test for clinical trials in China with equivalent performance to Guardant Health’s US-based laboratory test
April 2, 2024 HANGZHOU, China — Adicon Holdings Limited, a leading independent clinical laboratory company, announced today it now offers GuardantOMNI®, a
Adicon begins clinical trials sample testing upon completion of Analytical Validation Studies of the Guardant360® liquid biopsy in China
February 5, 2024 HANGZHOU, China — Adicon Holdings Limited, a leading independent clinical laboratory company, announced today that the first set of
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
January 8, 2024 SINGAPORE — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC (“Hikma”), a multinational pharmaceutical company,
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
September 5, 2023 SINGAPORE — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Japanese Ministry of Health, Labour
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
July 5, 2023 TOKYO — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has been informed it
Guardant Health Receives Regulatory Approval from Singapore’s Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers
May 30, 2023 SINGAPORE — Guardant Health, Inc. (Nasdaq: GH) announced today that Singapore’s Health Sciences Authority (HSA) has granted regulatory approval of Guardant360® CDx,
Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China
July 6, 2022 SINGAPORE — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Adicon Holdings Limited, a leading independent